

S3 Table. Prognostic factor analysis for recurrence-free survival

Variables (reference)	Univariate analysis			Multivariate analysis		
	HR	95% CI	p-value	HR	95% CI	p-value
Treatment (RFA)	1.422	0.988-2.046	0.06	-	-	-
Male sex	1.015	0.725-1.419	0.93	-	-	-
Age (≤ 70 yr)	1.000	0.684-1.463	> 0.99	-	-	-
CEA (< 6 ng/mL)	1.385	0.984-1.950	0.06	-	-	-
Pre-treatment systemic therapy (no) ^{a)}	2.158	1.419-3.281	< 0.001	1.944	1.265–2.988	0.002
Post-treatment systemic therapy (no) ^{a)}	2.183	1.478-3.226	< 0.001	2.059	1.374–3.085	< 0.001
Primary cancer AJCC stage (\leq II)	2.432	1.587-3.726	< 0.001	1.873	1.213–2.891	0.004
Primary cancer location (colon) ^{b)}	1.078	0.795-1.463	0.63	-	-	-
Liver tumor size (≤ 2 cm)	1.878	1.375-2.566	< 0.001	-	-	-
No. of liver metastasis (1)	1.306	0.956-1.700	0.09	-	-	-

AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; RFA, radiofrequency ablation. ^{a)}Compared with those who were treated with systemic therapy, ^{b)}Colon compared with rectum.